Christina (Tina) P./LinkedIn
Sep 14, 2026, 04:43
Christina (Tina) P.: Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
“Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Eye damage remains uncommon after 15 years, but certain factors increase the risk by John Gever, Contributing Writer, MedPage Today.
A recent meta-analysis details that the risk of retinopathy from long-term hydroxychloroquine (HCQ) treatment remains low initially but increases significantly after decades of continuous use.
Clinical guidelines recommend baseline eye exams and annual ophthalmologic screenings after five years of use to prevent permanent vision loss.
More posts featuring Christina (Tina) P. on Hemostasis Today.
-
Oct 10, 2026, 09:05Wolfgang Miesbach: Moving from Bleed Control to Comprehensive Joint Health
-
Oct 10, 2026, 07:59Leila Caroline Souza Reis: Enoxaparin Dosing for VTE Prevention in Adults With Obesity
-
Oct 10, 2026, 07:41Adeeb Bazuhair: New Evidence for Catheter Directed Thrombolysis in Acute PE
-
Oct 10, 2026, 07:22Poppy Clarke: Turning Steps Into Support for Thrombosis Awareness
-
Oct 10, 2026, 07:12Hamzah Khan: The Role of Genuine Curiosity in Driving High-Impact Academic Research
-
Oct 10, 2026, 06:58Nita Radhakrishnan: Turning Evidence Into Action for Hemophilia Care in India
-
Oct 10, 2026, 06:48Nutan Kaushik: HemeNext 2.0 Brings Global Perspectives to Hematology
-
Oct 10, 2026, 06:43Suthesh Sivapalaratnam: Advancing Bleeding Disorder Care at EHC 2026
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage